Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Nature Medicine July 1, 2024 Paul Glue, Colleen Loo, Johnson Fam et al. 60 citations
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with TRD and Montgomery-Asberg Depression...